期刊
NEUROBIOLOGY OF AGING
卷 100, 期 -, 页码 22-31出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2020.12.011
关键词
Alzheimer's disease; Amyloid; Hypertension; Dementia; Biomarkers
资金
- Alzheimer's Drug Discovery Foundation [20141208]
- Weston Brain Institute [20121211]
- Alzheimer's Association (USA)
- Brain Canada
- Canadian Institutes of Health Research [PJT-159711]
- Michael J. Fox Foundation
- Alzheimer's Research UK (BAND 3)
- Heart and Stroke Foundation Canadian Partnership for Stroke Recovery
- LC Campbell Cognitive Neurology Unit
- Sunnybrook Health Sciences Centre Department of Psychiatry
This study suggests that ARBs may be more effective than ACE-Is in protecting against memory decline by slowing amyloid-beta accumulation in certain brain regions. Differences in amyloid-beta accumulation rates between ARB and ACE-I users may be influenced by apolipoprotein E epsilon 4 carrier status. Further studies and clinical trials are needed to confirm the potential benefits of ARBs in Alzheimer's disease prevention and treatment.
Some studies suggest that angiotensin II type 1 receptor blockers (ARBs) may protect against memory decline more than angiotensin-converting enzyme inhibitors (ACE-Is), but few have examined possible mechanisms. We assessed longitudinal differences between ARB versus ACE-I users in global and sub-regional amyloid-beta accumulation by F-18-florbetapir. In cognitively normal older adults (n= 142), propensity-weighted linear mixed-effects models showed that ARB versus ACE-I use was associated with slower amyloid-beta accumulation in the cortex, and specifically in the caudal anterior cingulate and pre-cuneus, and in the precentral and postcentral gyri. In amyloid-positive participants with Alzheimer's disease dementia or mild cognitive impairment (n = 169), ARB versus ACE-I use was not associated with different rates of amyloid-beta accumulation. Apolipoprotein E epsilon 4 carrier status explained some heterogeneity in the different rates of amyloid-beta accumulation between users of ARBs versus ACE-Is in the study. Replicative studies and clinical trials are warranted to confirm potential benefits of ARBs on rates of amyloid-beta accumulation in the contexts of Alzheimer's disease prevention and treatment. (C) 2020 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据